Prostate cancer is one of the most dreaded forms of the disease - a major problem in men's health and in the medical community generally. Recent study results released by Medivation Inc. (MDVN) and Astellas Pharma showed that a mid-stage trial of an experimental drug showed some progress. This is the latest in a string of recent updates in the fight against the disease.
Here a few advancements (and one step back) in the battle to alleviate prostate cancer:
1. FDA Approved Trials Of ADXS-PSA Along With KEYTRUDA
Advaxis, Inc. (ADXS) said the FDA has approved its application to conduct trials of the combination of ADXS-PSA with KEYTRUDA in patients with previously treated, metastatic castration-resistant prostate cancer.
For more information, check out this story.
2. XTANDI Gets Approval In Europe
The drug XTANDI has received approval in Europe for the treatment of adult men with metastatic castration-resistant prostate cancer in certain situations.
For more information, check out this story.
3. Companies Sign Collaboration Deal For Zoptarelin doxorubicin
Aeterna Zentaris Inc. (AEZS) Monday said it signed a license and technology transfer agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for its cancer drug. The deal covers China, Hong Kong and Macau.
For more information, check out this story.
4. Cabozantinib Fails In Trial
Every step forward in the fight against prostate cancer comes with at least a small bit of failure. Exelixis Inc. (EXEL) recently saw its trial miss its primary endpoint - an announcement that sent shares sharply lower.
For more information, check out this story.
For comments and feedback contact: editorial@rttnews.com
Health News